NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Syros Pharmaceuticals Inc (NASDAQ:SYRS) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.01. The business earned $0.56 million during the quarter, compared to analyst estimates of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. View Syros Pharmaceuticals' Earnings History.

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals.

7 equities research analysts have issued 1 year price targets for Syros Pharmaceuticals' stock. Their forecasts range from $10.00 to $18.00. On average, they expect Syros Pharmaceuticals' share price to reach $14.50 in the next year. This suggests a possible upside of 216.2% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.

Media stories about SYRS stock have trended neutral on Friday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Syros Pharmaceuticals.

Syros Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 2,590,000 shares, an increase of 8.8% from the October 31st total of 2,380,000 shares. Based on an average trading volume of 234,100 shares, the days-to-cover ratio is presently 11.1 days. Currently, 8.6% of the shares of the stock are short sold. View Syros Pharmaceuticals' Current Options Chain.

Some companies that are related to Syros Pharmaceuticals include CannTrust (CNTTF), Eagle Pharmaceuticals (EGRX), TG Therapeutics (TGTX), Aurinia Pharmaceuticals (AUPH), Revance Therapeutics (RVNC), Akebia Therapeutics (AKBA), Kura Oncology (KURA), ANI Pharmaceuticals (ANIP), Flexion Therapeutics (FLXN), Homology Medicines (FIXX), Synthorx (THOR), Collegium Pharmaceutical (COLL), TherapeuticsMD (TXMD), Axovant Sciences (AXON) and Phathom Pharmaceuticals (PHAT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO), ImmunoGen (IMGN), ZIOPHARM Oncology (ZIOP), Zynerba Pharmaceuticals (ZYNE), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD) and Global Blood Therapeutics (GBT).

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Syros Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (10.92%), Sumitomo Mitsui Trust Holdings Inc. (10.92%), Redmile Group LLC (9.16%), State Street Corp (1.59%), Millennium Management LLC (0.04%) and Barclays PLC (0.04%). Company insiders that own Syros Pharmaceuticals stock include Jeremy P Springhorn, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View Institutional Ownership Trends for Syros Pharmaceuticals.

SYRS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Richard A Young and Venture Fund Vii LP Arch. View Insider Buying and Selling for Syros Pharmaceuticals.

SYRS stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Redmile Group LLC, State Street Corp, Millennium Management LLC, Metropolitan Life Insurance Co NY and Tower Research Capital LLC TRC . Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYRS stock can currently be purchased for approximately $4.59.

Syros Pharmaceuticals has a market capitalization of $194.59 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.

The official website for Syros Pharmaceuticals is http://www.syros.com/.

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]